Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

  • There is currently no data for POLX

Director Dealing

22 Jan 2020 16:03

RNS Number : 6364A
Polarean Imaging PLC
22 January 2020
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

Director Dealing

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that yesterday it was notified that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 337,574 Ordinary Shares of £0.00037 ("Ordinary Shares") at an average price of 29.6 pence per share on 20 January 2020.

Following this transaction, Dr Allis now holds a beneficial interest in 1,877,574 Ordinary Shares, representing approximately 1.64 per cent. of the Company's issued share capital.

 

Enquiries: 

 

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com 

Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

Richard Morgan, Chairman 

 

 

 

SP Angel Corporate Finance LLP 

Tel: +44 (0)20 3470 0470  

David Hignell / Soltan Tagiev (Corporate Finance) 

 

Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Dr Jonathan Allis

2.

Reason for the notification

a)

Position/status:

Non-Executive Director

b)

Initial notification/Amendment:

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Polarean Imaging Plc

b)

LEI:

213800DGR2BHXJ36OL37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

 

Ordinary shares of £0.00037

GB00BF3DT583

b)

Nature of the transaction:

Purchase of shares

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

29.9 pence

33,444

29.9 pence

33,444

29.9 pence

33,444

29.5 pence

33,898

29.5 pence

67,796

29.5 pence

50,847

29.5 pence

50,803

29.5 pence

33,898

 

d)

Aggregated information:

Aggregated volume:

Price:

 

Price(s)

Volume(s)

29.6 pence

337,574

 

 

 

e)

Date of the transaction:

20 January 2020

f)

Place of the transaction:

AIM, London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGZGZMVZGGGZM
Date   Source Headline
19th Jun 20244:10 pmRNSHolding(s) in Company
19th Jun 20244:10 pmRNSHolding(s) in Company
19th Jun 20243:55 pmRNSHolding(s) in Company
19th Jun 20247:00 amRNSHolding(s) in Company
18th Jun 20245:38 pmRNSHolding(s) in Company
18th Jun 20245:37 pmRNSHolding(s) in Company
14th Jun 20242:48 pmRNSResult of GM, Open Offer Update and TVR
23rd May 20247:00 amRNSPosting of Circular
22nd May 20247:00 amRNSResult of Placing
21st May 20244:51 pmRNSProposed Placing, Subscription and Open Offer
10th May 20247:00 amRNSNew Xenon MRI System order received
8th May 20247:00 amRNSXenon MRI to be featured at ATS 2024 conference
3rd May 20247:00 amRNSOrder received for upgraded hyperpolariser
16th Apr 20247:00 amRNSU.S. Patent granted for Xenon MRI
14th Mar 20247:00 amRNSExercise of Warrants, Issue of Equity and TVR
12th Mar 20243:59 pmRNSHolding(s) in Company
29th Feb 20247:00 amRNS2024 Polarean Strategy Update
26th Jan 20247:00 amRNSBlock Listing Six Monthly Return
15th Jan 20247:00 amRNSComment re: share purchase
12th Jan 20245:00 pmRNSHolding(s) in Company
12th Jan 20245:00 pmRNSHolding(s) in Company
7th Dec 20237:00 amRNSCompany Update
27th Nov 20237:00 amRNSHolding(s) in Company
27th Sep 20231:59 pmRNSDirectorate Change
8th Sep 20237:00 amRNSPartnership with VIDA
7th Sep 20234:54 pmRNSHalf-year Report
7th Sep 20237:00 amRNSHalf-year Report
5th Sep 202311:51 amRNSReimbursement code price range for XENOVIEW
29th Aug 20237:00 amRNSCMS grants reimbursement code for XENOVIEW
21st Aug 20235:29 pmRNSHolding(s) in Company
15th Aug 20237:00 amRNSNotice of Results
7th Aug 20237:00 amRNSExercise of Warrants
3rd Aug 20237:00 amRNSClearance received for new MRI chest coil
31st Jul 20237:00 amRNSClinical imaging with XENOVIEW in Missouri
27th Jul 20237:00 amRNSBlock Listing Six Monthly Return
30th Jun 20237:00 amRNSExercise of Warrants
28th Jun 20233:00 pmRNSResult of AGM
21st Jun 20237:00 amRNSAppointment of Dr. Christopher von Jako as new CEO
2nd Jun 20233:00 pmRNSCollaboration with Philips at ISMRM 2023
2nd Jun 20237:00 amRNSExtension of Warrants
26th May 20237:00 amRNSFinal Results
11th May 20232:42 pmRNSFirst clinical scan using XENOVIEW in Cincinnati
3rd May 20235:00 pmRNSFeatured at 2023 ATS Respiratory Innovation Summit
26th Apr 20237:00 amRNSFirst order for XENOVIEW gas blend received
17th Apr 20237:00 amRNSAppointment of Dan Brague as consultant
14th Mar 20237:30 amRNSRestoration - Polarean Imaging PLC
14th Mar 20237:00 amRNSRequest for temporary suspension to be lifted
13th Mar 20237:30 amRNSSuspension - Polarean Imaging PLC
13th Mar 20237:00 amRNSSilicon Valley Bank Relationship
20th Feb 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.